ArticleBiomedicines2023
Use of Biomarkers to Improve 28-Day Mortality Stratification in Patients with Sepsis and SOFA ≤ 6.
Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Update on sepsis treatment.Journal of intensive care · 2026Review
- Clinical Performance of BIO-S and BIO-SC Composite Bioscores for 28-Day Mortality Stratification in Adults with Sepsis and Septic Shock.Biomedicines · 2026Article
- Article
- Progranulin Is a Useful Biomarker to Predict Mortality in ICU Patients with Low Burden of Organ Dysfunction.Biomedicines · 2026Article
- Exploring proteomic signatures in sepsis and non-infectious systemic inflammatory response syndrome.PloS one · 2026Observational
- Prognostic Value of 48-h Biomarker Changes in Sepsis Mortality.Journal of clinical medicine · 2025Article
- Circulating histones as clinical biomarkers in critically ill conditions.FEBS letters · 2025Review
- Biomarkers Affecting Treatment Outcomes of Febrile Neutropenia in Hematological Patients with Lymphomas: Is Presepsin the New Promising Diagnostic and Prognostic Biomarker?Journal of clinical medicine · 2025Article
- Sepsis Biomarkers: Advancements and Clinical Applications-A Narrative Review.International journal of molecular sciences · 2024Review
- Can We Improve Mortality Prediction in Patients with Sepsis in the Emergency Department?Medicina (Kaunas, Lithuania) · 2024Observational
- SOFA in sepsis: with or without GCS.European journal of medical research · 2024Article
- Review
- Review
- Current perspectives in the management of sepsis and septic shock.Frontiers in medicine · 2024Review
- SPINK1 is a Potential Diagnostic and Prognostic Biomarker for Sepsis.Infection and drug resistance · 2024Article
- Mid-Regional Pro-Adrenomedullin Can Predict Organ Failure and Prognosis in Sepsis?International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Early diagnosis and appropriate treatments are crucial to reducing mortality risk in septic patients. Low SOFA scores and current biomarkers may not adequately discern patients that could develop severe organ dysfunction or have an elevated mortality risk. The aim of this prospective observational study was to evaluate the predictive value of the biomarkers mid-regional pro-adrenomedullin (MR-proADM), procalcitonin (PCT), C-reactive protein (CRP), and lactate for 28-day mortality in patients with sepsis, and patients with a SOFA score ≤6. 284 were included, with a 28-day all-cause mortality of 8.45% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.